[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Entrectinib.]
[M04AB02, sulfinpyrazone, The metabolism of Entrectinib can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Entrectinib.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Entrectinib.]
[L02BA01, tamoxifen, The metabolism of Entrectinib can be increased when combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Entrectinib can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Entrectinib.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Entrectinib.]
[G03BA03, testosterone, The metabolism of Entrectinib can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Entrectinib.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Entrectinib can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Entrectinib.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Entrectinib.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Entrectinib.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Entrectinib.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Entrectinib.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Entrectinib.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Entrectinib.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Entrectinib.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Entrectinib.]
[S01BA05, triamcinolone, The metabolism of Entrectinib can be increased when combined with Triamcinolone.]
[R03BA07, mometasone, The metabolism of Entrectinib can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Entrectinib.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Entrectinib.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Entrectinib.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Entrectinib.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Entrectinib.]
[J01FA08, troleandomycin, The metabolism of Entrectinib can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The metabolism of Entrectinib can be decreased when combined with Roflumilast.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Entrectinib.]
[A10BH05, linagliptin, The metabolism of Entrectinib can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Entrectinib can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Entrectinib can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Entrectinib.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Entrectinib.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Entrectinib.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Entrectinib.]
[B01AC24, ticagrelor, The metabolism of Entrectinib can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Entrectinib can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Entrectinib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Entrectinib can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Entrectinib.]
[A11HA03, vitamin E, The metabolism of Entrectinib can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Entrectinib can be increased when combined with Warfarin.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Entrectinib.]
[J05AE02, indinavir, The metabolism of Entrectinib can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Entrectinib can be increased when combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Entrectinib.]
[L01ED01, crizotinib, The metabolism of Entrectinib can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Entrectinib can be decreased when combined with Zafirlukast.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Entrectinib.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Entrectinib.]
[N05AE04, ziprasidone, The metabolism of Entrectinib can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Entrectinib can be decreased when combined with Drospirenone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Entrectinib.]
[J02AC03, voriconazole, The metabolism of Entrectinib can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Entrectinib.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Entrectinib.]
[R07AX02, ivacaftor, The metabolism of Entrectinib can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Entrectinib can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Entrectinib.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Entrectinib.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Entrectinib.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Entrectinib.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Entrectinib.]
[V03AX03, cobicistat, The metabolism of Entrectinib can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Entrectinib can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The metabolism of Entrectinib can be increased when combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Entrectinib.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Entrectinib.]
[N05CA04, barbital, The metabolism of Entrectinib can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Entrectinib can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Entrectinib.]
[N03AX22, perampanel, The metabolism of Entrectinib can be increased when combined with Perampanel.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Entrectinib.]
[G04BE03, sildenafil, The serum concentration of Sildenafil can be increased when it is combined with Entrectinib.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Entrectinib.]
[C10AX12, lomitapide, The metabolism of Entrectinib can be decreased when combined with Lomitapide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Entrectinib.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Entrectinib.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Entrectinib can be increased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Entrectinib.]
[A10BK02, canagliflozin, The serum concentration of Canagliflozin can be increased when it is combined with Entrectinib.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Entrectinib.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Entrectinib.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Entrectinib.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Entrectinib.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Benzocaine.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Entrectinib.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Entrectinib.]
[L01EC02, dabrafenib, The metabolism of Entrectinib can be increased when combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Entrectinib.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Entrectinib.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Entrectinib.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Bepridil is combined with Entrectinib.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Entrectinib.]
[N03AF04, eslicarbazepine, The metabolism of Entrectinib can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Entrectinib can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Entrectinib.]
[C07AB04, acebutolol, The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Entrectinib.]
[N05CH03, tasimelteon, The metabolism of Entrectinib can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Entrectinib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Entrectinib can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Entrectinib can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Entrectinib can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Entrectinib.]
[L04AC11, siltuximab, The metabolism of Entrectinib can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Entrectinib.]
[B01AC26, vorapaxar, The metabolism of Entrectinib can be decreased when combined with Vorapaxar.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Entrectinib.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Entrectinib.]
[L01EM01, idelalisib, The metabolism of Entrectinib can be decreased when combined with Idelalisib.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Entrectinib.]
[N05CM19, suvorexant, The metabolism of Entrectinib can be decreased when combined with Suvorexant.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Entrectinib.]
[J01XA05, oritavancin, The metabolism of Entrectinib can be increased when combined with Oritavancin.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Entrectinib.]
[L01EX09, nintedanib, The metabolism of Entrectinib can be decreased when combined with Nintedanib.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Entrectinib.]
[L01XK01, olaparib, The metabolism of Entrectinib can be decreased when combined with Olaparib.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Entrectinib.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Entrectinib.]
[L04AC10, secukinumab, The metabolism of Entrectinib can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Entrectinib can be decreased when combined with Palbociclib.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Entrectinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Entrectinib.]
[N02BE01, acetaminophen, The metabolism of Entrectinib can be increased when combined with Acetaminophen.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Entrectinib.]
[J05AP06, asunaprevir, The metabolism of Entrectinib can be increased when combined with Asunaprevir.]
[S01EC01, acetazolamide, The metabolism of Entrectinib can be decreased when combined with Acetazolamide.]
[J02AC05, isavuconazole, The metabolism of Entrectinib can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Entrectinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Entrectinib.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Entrectinib.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Entrectinib.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Entrectinib.]
[M04AB05, lesinurad, The metabolism of Entrectinib can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Entrectinib.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Entrectinib.]
[N05CA05, aprobarbital, The metabolism of Entrectinib can be increased when combined with Aprobarbital.]
[L01XX52, venetoclax, The metabolism of Entrectinib can be decreased when combined with Venetoclax.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Entrectinib.]
[C08CA01, amlodipine, The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Entrectinib.]
[N05AX17, pimavanserin, The metabolism of Entrectinib can be decreased when combined with Pimavanserin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Entrectinib.]
[N07BC01, buprenorphine, The metabolism of Entrectinib can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Entrectinib.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Entrectinib.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Artemether is combined with Entrectinib.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Entrectinib.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Entrectinib.]
[L01XK03, rucaparib, The metabolism of Entrectinib can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Entrectinib.]
[L01EF02, ribociclib, The metabolism of Entrectinib can be decreased when combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Entrectinib.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Entrectinib.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Entrectinib can be increased when combined with Calcitriol.]
[J05AE09, tipranavir, The metabolism of Entrectinib can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Entrectinib.]
[L04AB02, infliximab, The metabolism of Entrectinib can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Entrectinib can be increased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Entrectinib.]
[L04AC14, sarilumab, The metabolism of Entrectinib can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Entrectinib.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Entrectinib.]
[D01AC10, bifonazole, The metabolism of Entrectinib can be decreased when combined with Bifonazole.]
[L01XX59, enasidenib, The metabolism of Entrectinib can be increased when combined with Enasidenib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Entrectinib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Entrectinib.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Entrectinib.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Entrectinib.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Entrectinib.]
[J05AG03, efavirenz, The metabolism of Entrectinib can be increased when combined with Efavirenz.]
[R03BA02, budesonide, The metabolism of Entrectinib can be increased when combined with Budesonide.]
[L01EL02, acalabrutinib, The metabolism of Entrectinib can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Entrectinib can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Entrectinib.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Entrectinib.]
[N01BX04, capsaicin, The metabolism of Entrectinib can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Ertugliflozin can be increased when it is combined with Entrectinib.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Entrectinib.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Macimorelin is combined with Entrectinib.]
[L02BB05, apalutamide, The metabolism of Entrectinib can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Entrectinib can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Entrectinib.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Entrectinib.]
[B02BX09, fostamatinib, The metabolism of Entrectinib can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Entrectinib can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Entrectinib.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Entrectinib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Entrectinib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Entrectinib.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Entrectinib.]
[L01XX62, ivosidenib, The metabolism of Entrectinib can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Entrectinib can be increased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Entrectinib.]
[J05AX24, tecovirimat, The metabolism of Entrectinib can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Entrectinib can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Entrectinib.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Entrectinib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Entrectinib.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Chloroprocaine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Entrectinib.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Entrectinib.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Entrectinib.]
[L01ED05, lorlatinib, The metabolism of Entrectinib can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Entrectinib can be increased when combined with Emapalumab.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Entrectinib.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Entrectinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Entrectinib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Entrectinib.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Entrectinib.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Entrectinib.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Entrectinib.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Entrectinib.]
[N06AX27, esketamine, The metabolism of Entrectinib can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Entrectinib can be decreased when combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Entrectinib can be decreased when combined with Clarithromycin.]
[N05BA09, clobazam, The metabolism of Entrectinib can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Entrectinib can be increased when combined with Cloprednol.]
[L04AB01, etanercept, The metabolism of Entrectinib can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Entrectinib can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Entrectinib can be increased when combined with Alpelisib.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Entrectinib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Entrectinib.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Entrectinib.]
[S01AA13, fusidic acid, The metabolism of Entrectinib can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Entrectinib.]
[N07XX11, pitolisant, The metabolism of Entrectinib can be increased when combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Entrectinib can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Entrectinib.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Entrectinib.]
[J01DB01, cephalexin, The metabolism of Entrectinib can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Entrectinib can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Entrectinib can be increased when combined with Deflazacort.]
[N02CC08, lasmiditan, The serum concentration of Lasmiditan can be increased when it is combined with Entrectinib.]
[B06AX03, voxelotor, The serum concentration of Entrectinib can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The metabolism of Entrectinib can be increased when combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Entrectinib.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Entrectinib.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Entrectinib.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Entrectinib.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Entrectinib.]
[L01XX72, tazemetostat, The metabolism of Entrectinib can be decreased when combined with Tazemetostat.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Entrectinib.]
[J05AB16, remdesivir, The metabolism of Entrectinib can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Entrectinib.]
[H02CA02, osilodrostat, The metabolism of Entrectinib can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Entrectinib can be increased when combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Entrectinib.]
[M01AH02, rofecoxib, The metabolism of Entrectinib can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Entrectinib can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Entrectinib can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Entrectinib can be decreased when combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Entrectinib can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Entrectinib can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Entrectinib.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Entrectinib.]
[D07XB03, fluprednidene, The metabolism of Entrectinib can be increased when combined with Fluprednidene.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Entrectinib.]
[L01EX22, selpercatinib, The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Entrectinib.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Entrectinib.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Entrectinib.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Entrectinib.]
[L04AC19, satralizumab, The serum concentration of Entrectinib can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Entrectinib.]
[L01EX23, pralsetinib, The metabolism of Entrectinib can be increased when combined with Pralsetinib.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Entrectinib.]
[N05AA01, chlorpromazine, The metabolism of Entrectinib can be increased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Entrectinib.]
[B06AC06, berotralstat, The metabolism of Entrectinib can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Entrectinib can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Entrectinib.]
[L04AD03, voclosporin, The serum concentration of Voclosporin can be increased when it is combined with Entrectinib.]
[P03AX07, abametapir, The serum concentration of Entrectinib can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Entrectinib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Entrectinib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Entrectinib.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Entrectinib.]
[R03BA03, flunisolide, The metabolism of Entrectinib can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Entrectinib can be increased when combined with Fluocinolone acetonide.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Entrectinib.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Entrectinib.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Entrectinib.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Entrectinib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Entrectinib.]
[A02BA01, cimetidine, The metabolism of Entrectinib can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Entrectinib.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Entrectinib.]
[L01XX73, sotorasib, The serum concentration of Entrectinib can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Entrectinib can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Entrectinib can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Citalopram is combined with Entrectinib.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Entrectinib is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Entrectinib can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Entrectinib is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Entrectinib can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Entrectinib.]
[N06AX25, St. John's wort extract, The metabolism of Entrectinib can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Entrectinib can be increased when it is combined with Asciminib.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Entrectinib.]
[C10AB01, clofibrate, The metabolism of Entrectinib can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Entrectinib can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Entrectinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Entrectinib.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Entrectinib.]
[C01EB24, mavacamten, The metabolism of Entrectinib can be increased when combined with Mavacamten.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Entrectinib.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Entrectinib.]
[J05AX31, lenacapavir, The metabolism of Entrectinib can be decreased when combined with Lenacapavir.]
[L01XX77, adagrasib, The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Entrectinib.]
[N05AH02, clozapine, The metabolism of Entrectinib can be increased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Entrectinib.]
[H01AC08, somatrogon, The metabolism of Entrectinib can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Cocaine is combined with Entrectinib.]
[L04AC21, bimekizumab, The metabolism of Entrectinib can be increased when combined with Bimekizumab.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Entrectinib.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Entrectinib.]
[J01FA15, telithromycin, The metabolism of Entrectinib can be decreased when combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Entrectinib.]
[J02AC02, itraconazole, The metabolism of Entrectinib can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Entrectinib.]
[N05BA10, ketazolam, The metabolism of Entrectinib can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Entrectinib.]
[J02AC04, posaconazole, The metabolism of Entrectinib can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Entrectinib.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Entrectinib.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Entrectinib.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Entrectinib.]
[S01BA03, cortisone, The metabolism of Entrectinib can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Entrectinib.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Entrectinib.]
[C08CA11, manidipine, The metabolism of Entrectinib can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The metabolism of Entrectinib can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Entrectinib.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Entrectinib.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Entrectinib.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Entrectinib.]
[J01FA03, midecamycin, The metabolism of Entrectinib can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Entrectinib.]
[L01AA01, cyclophosphamide, The metabolism of Entrectinib can be increased when combined with Cyclophosphamide.]
[S01XA18, cyclosporine, The metabolism of Entrectinib can be decreased when combined with Cyclosporine.]
[N06BA07, modafinil, The metabolism of Entrectinib can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Entrectinib.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Entrectinib.]
[C10AA07, rosuvastatin, The metabolism of Entrectinib can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Entrectinib can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Entrectinib.]
[M01AH05, etoricoxib, The metabolism of Entrectinib can be decreased when combined with Etoricoxib.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Entrectinib.]
[G03XA01, danazol, The metabolism of Entrectinib can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The metabolism of Entrectinib can be decreased when combined with Daunorubicin.]
[N06AX06, nefazodone, The metabolism of Entrectinib can be decreased when combined with Nefazodone.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Entrectinib.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Entrectinib.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Entrectinib.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Entrectinib.]
[N03AF02, oxcarbazepine, The metabolism of Entrectinib can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Entrectinib can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Entrectinib can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Entrectinib can be increased when combined with Adalimumab.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Entrectinib.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Cinchocaine.]
[J01CF01, dicloxacillin, The metabolism of Entrectinib can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Entrectinib.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Entrectinib.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Entrectinib.]
[L02AA01, diethylstilbestrol, The metabolism of Entrectinib can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Entrectinib can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Entrectinib can be increased when combined with Difluocortolone.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Entrectinib.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Entrectinib.]
[C04AE04, dihydroergocristine, The metabolism of Entrectinib can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Entrectinib can be decreased when combined with Dihydroergotamine.]
[J05AE08, atazanavir, The metabolism of Entrectinib can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Entrectinib.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Entrectinib.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Entrectinib can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Entrectinib.]
[M02AX03, dimethyl sulfoxide, The metabolism of Entrectinib can be decreased when combined with Dimethyl sulfoxide.]
[C05CA03, diosmin, The metabolism of Entrectinib can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Entrectinib.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Cisapride is combined with Entrectinib.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Entrectinib.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Entrectinib.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Entrectinib.]
[S02AA12, rifamycin SV, The metabolism of Entrectinib can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Entrectinib can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Entrectinib.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Entrectinib.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Entrectinib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Entrectinib.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Entrectinib.]
[A04AD12, aprepitant, The metabolism of Entrectinib can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Entrectinib.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Entrectinib.]
[J05AE07, fosamprenavir, The metabolism of Entrectinib can be decreased when combined with Fosamprenavir.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Entrectinib.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Entrectinib.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Entrectinib.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Entrectinib.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Entrectinib.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Entrectinib.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Entrectinib.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Entrectinib.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Entrectinib.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Entrectinib.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Entrectinib.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Entrectinib.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Entrectinib.]
[G01AF05, econazole, The metabolism of Entrectinib can be decreased when combined with Econazole.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Entrectinib.]
[H01AA01, corticotropin, The metabolism of Entrectinib can be increased when combined with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Entrectinib.]
[D01BA02, terbinafine, The metabolism of Entrectinib can be increased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Terodiline is combined with Entrectinib.]
[G01AF08, tioconazole, The metabolism of Entrectinib can be decreased when combined with Tioconazole.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Entrectinib.]
[N03AX11, topiramate, The metabolism of Entrectinib can be increased when combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Entrectinib.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Entrectinib.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Entrectinib.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Entrectinib.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Entrectinib.]
[C08CA12, mepirodipine, The metabolism of Entrectinib can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Entrectinib can be decreased when combined with Epinephrine.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Entrectinib.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Entrectinib.]
[N02CA02, ergotamine, The metabolism of Entrectinib can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Entrectinib can be decreased when combined with Erythromycin.]
[J04AK02, ethambutol, The metabolism of Entrectinib can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Entrectinib can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Entrectinib can be increased when combined with Fluticasone.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Entrectinib.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Entrectinib.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Etidocaine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Entrectinib.]
[N05AE03, sertindole, The risk or severity of QTc prolongation can be increased when Sertindole is combined with Entrectinib.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Entrectinib.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Entrectinib.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Entrectinib.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Astemizole is combined with Entrectinib.]
[R06AX12, terfenadine, The metabolism of Entrectinib can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Entrectinib can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Entrectinib.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entrectinib.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Entrectinib.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Entrectinib.]
[P02CA03, albendazole, The metabolism of Entrectinib can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Entrectinib.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Entrectinib.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Entrectinib.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Flecainide is combined with Entrectinib.]
[J01CF05, floxacillin, The metabolism of Entrectinib can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Entrectinib can be decreased when combined with Fluconazole.]
[D07AC08, fluocinonide, The metabolism of Entrectinib can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Entrectinib can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Entrectinib can be increased when combined with Ethanol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Entrectinib.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Entrectinib.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Entrectinib.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Entrectinib.]
[J05AE10, darunavir, The metabolism of Entrectinib can be decreased when combined with Darunavir.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Entrectinib.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Entrectinib.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Entrectinib.]
[N03AA04, barbexaclone, The metabolism of Entrectinib can be increased when combined with Barbexaclone.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Entrectinib.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Entrectinib.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Entrectinib.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Entrectinib.]
[J05AG04, etravirine, The metabolism of Entrectinib can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Entrectinib.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Entrectinib.]
[A10BB01, glyburide, The metabolism of Entrectinib can be decreased when combined with Glyburide.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Entrectinib.]
[C02CA04, doxazosin, The metabolism of Entrectinib can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Entrectinib.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Entrectinib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Entrectinib.]
[D01BA01, griseofulvin, The metabolism of Entrectinib can be increased when combined with Griseofulvin.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entrectinib.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Entrectinib.]
[N05AD01, haloperidol, The metabolism of Entrectinib can be decreased when combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Entrectinib.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Entrectinib.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Entrectinib.]
[G03DC01, allylestrenol, The metabolism of Entrectinib can be decreased when combined with Allylestrenol.]
[C08CA10, nilvadipine, The metabolism of Entrectinib can be decreased when combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Entrectinib.]
[C02DB02, hydralazine, The metabolism of Entrectinib can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Entrectinib.]
[S02BA01, hydrocortisone, The metabolism of Entrectinib can be increased when combined with Hydrocortisone.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Entrectinib.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Entrectinib is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Entrectinib can be increased when combined with Rifabutin.]
[L01AA06, ifosfamide, The metabolism of Entrectinib can be increased when combined with Ifosfamide.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Entrectinib.]
[L01CD01, paclitaxel, The metabolism of Entrectinib can be increased when combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Entrectinib.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Entrectinib.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Entrectinib.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Entrectinib.]
[N06AX17, milnacipran, The metabolism of Entrectinib can be decreased when combined with Milnacipran.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Sitagliptin can be increased when it is combined with Entrectinib.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Entrectinib.]
[C10AA06, cerivastatin, The metabolism of Entrectinib can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Entrectinib.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Entrectinib.]
[J04AC01, isoniazid, The metabolism of Entrectinib can be decreased when combined with Isoniazid.]
[L04AC07, tocilizumab, The metabolism of Entrectinib can be increased when combined with Tocilizumab.]
[J02AB02, ketoconazole, The metabolism of Entrectinib can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Entrectinib can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Entrectinib.]
[V03AC03, deferasirox, The metabolism of Entrectinib can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Entrectinib can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Entrectinib.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Entrectinib.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Entrectinib.]
[N03AX18, lacosamide, The metabolism of Entrectinib can be decreased when combined with Lacosamide.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Entrectinib.]
[N06BA13, armodafinil, The metabolism of Entrectinib can be increased when combined with Armodafinil.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Entrectinib.]
[C10AA02, lovastatin, The metabolism of Entrectinib can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Entrectinib.]
[L01EA03, nilotinib, The metabolism of Entrectinib can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Entrectinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Entrectinib.]
[C01AA08, medigoxin, Entrectinib may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Entrectinib.]
[N02AB02, meperidine, The metabolism of Entrectinib can be decreased when combined with Meperidine.]
[N03AA01, mephobarbital, The metabolism of Entrectinib can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Entrectinib can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Entrectinib.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Entrectinib.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Entrectinib.]
[H01CB03, lanreotide, The metabolism of Entrectinib can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Entrectinib.]
[H03BB02, methimazole, The metabolism of Entrectinib can be decreased when combined with Methimazole.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Entrectinib.]
[V04CG05, methylene blue, The metabolism of Entrectinib can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Entrectinib can be decreased when combined with Methylergometrine.]
[H02AB04, methylprednisolone, The metabolism of Entrectinib can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Entrectinib can be increased when combined with Rufinamide.]
[N02CA04, methysergide, The metabolism of Entrectinib can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Entrectinib.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Entrectinib.]
[V04CD01, metyrapone, The metabolism of Entrectinib can be increased when combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Entrectinib can be decreased when combined with Miconazole.]
[N05CD08, midazolam, The metabolism of Entrectinib can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The metabolism of Entrectinib can be increased when combined with Mifepristone.]
[J01FA11, miocamycin, The metabolism of Entrectinib can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Entrectinib can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, The metabolism of Entrectinib can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Entrectinib can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Entrectinib.]
[N02AA01, morphine, The serum concentration of Morphine can be increased when it is combined with Entrectinib.]
[L04AB05, certolizumab pegol, The metabolism of Entrectinib can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Entrectinib.]
[N05CA02, amobarbital, The metabolism of Entrectinib can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Entrectinib.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Entrectinib.]
[G03XC01, raloxifene, The metabolism of Entrectinib can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Entrectinib.]
[N03AB05, fosphenytoin, The metabolism of Entrectinib can be increased when combined with Fosphenytoin.]
[J01CF06, nafcillin, The metabolism of Entrectinib can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Entrectinib can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Entrectinib can be increased when combined with Anakinra.]
[A10BG01, troglitazone, The metabolism of Entrectinib can be increased when combined with Troglitazone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Entrectinib.]
[L01CD02, docetaxel, The metabolism of Entrectinib can be decreased when combined with Docetaxel.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Entrectinib.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Entrectinib.]
[N06AX23, desvenlafaxine, The metabolism of Entrectinib can be decreased when combined with Desvenlafaxine.]
[C10AD02, niacin, The metabolism of Entrectinib can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Entrectinib can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Entrectinib.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Entrectinib.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Entrectinib.]
[G03DC02, norethindrone, The metabolism of Entrectinib can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Entrectinib.]
[C02KX01, bosentan, The metabolism of Entrectinib can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Entrectinib.]
[R05DA07, noscapine, The metabolism of Entrectinib can be decreased when combined with Noscapine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entrectinib.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Entrectinib.]
[J01FA05, oleandomycin, The metabolism of Entrectinib can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Entrectinib can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Entrectinib can be increased when combined with Omeprazole.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Entrectinib.]
[C07AA02, oxprenolol, The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Entrectinib.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entrectinib.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Asenapine is combined with Entrectinib.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Entrectinib.]
[H02AB05, paramethasone, The metabolism of Entrectinib can be increased when combined with Paramethasone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Entrectinib.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Entrectinib.]
[N05CA01, pentobarbital, The metabolism of Entrectinib can be increased when combined with Pentobarbital.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Entrectinib.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Entrectinib.]
[N03AA02, phenobarbital, The metabolism of Entrectinib can be increased when combined with Phenobarbital.]
[M02AA01, phenylbutazone, The metabolism of Entrectinib can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Entrectinib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Entrectinib can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Entrectinib.]
[L02BB03, bicalutamide, The metabolism of Entrectinib can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Entrectinib.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Pimozide is combined with Entrectinib.]
[J05AE01, saquinavir, The metabolism of Entrectinib can be decreased when combined with Saquinavir.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Entrectinib.]
[J05AG02, delavirdine, The metabolism of Entrectinib can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Entrectinib can be decreased when combined with Irbesartan.]
[L04AC08, canakinumab, The metabolism of Entrectinib can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The metabolism of Entrectinib can be decreased when combined with Ritonavir.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Entrectinib.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Entrectinib.]
[S03BA02, prednisolone, The metabolism of Entrectinib can be increased when combined with Prednisolone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Entrectinib.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Entrectinib.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Entrectinib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Entrectinib can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Entrectinib can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Entrectinib.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Entrectinib.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Procaine.]
[C10AB05, fenofibrate, The metabolism of Entrectinib can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Entrectinib.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Entrectinib.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Entrectinib.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Entrectinib.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Entrectinib.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Entrectinib.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Entrectinib.]
[N02AC04, propoxyphene, The metabolism of Entrectinib can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The risk or severity of QTc prolongation can be increased when Propranolol is combined with Entrectinib.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Entrectinib.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Entrectinib.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Entrectinib.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Entrectinib.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Quinidine is combined with Entrectinib.]
[P01BC01, quinine, The metabolism of Entrectinib can be increased when combined with Quinine.]
[J04AB02, rifampin, The metabolism of Entrectinib can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Entrectinib.]
[N05CA06, secobarbital, The metabolism of Entrectinib can be increased when combined with Secobarbital.]
[H01CB01, somatostatin, The metabolism of Entrectinib can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Entrectinib.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Entrectinib.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Entrectinib.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Entrectinib.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Entrectinib.]
[D07AB02, hydrocortisone butyrate, The metabolism of Entrectinib can be increased when combined with Hydrocortisone butyrate.]
